These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 9037281)

  • 1. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
    Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction.
    Witjes WP; Robertson A; Rosier PF; Neal DE; Debruyne FM; de la Rosette JJ
    Urology; 1997 Jul; 50(1):55-61. PubMed ID: 9218019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
    J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of terazosin on functional bladder outlet obstruction in women: a pilot study.
    Kessler TM; Studer UE; Burkhard FC
    J Urol; 2006 Oct; 176(4 Pt 1):1487-92. PubMed ID: 16952666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
    Rossi C; Kortmann BB; Sonke GS; Floratos DL; Kiemeney LA; Wijkstra H; de la ROSETTE JJ
    J Urol; 2001 Jan; 165(1):38-41. PubMed ID: 11125359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
    Lee JY; Kim HW; Lee SJ; Koh JS; Suh HJ; Chancellor MB
    BJU Int; 2004 Oct; 94(6):817-20. PubMed ID: 15476515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction.
    Sriplakich S; Promwatcharanon K
    J Med Assoc Thai; 2007 Nov; 90(11):2326-31. PubMed ID: 18181315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study.
    Koritsiadis G; Stravodimos K; Mitropoulos D; Doumanis G; Fokitis I; Koritsiadis S; Constantinides C
    BJU Int; 2008 Jun; 101(12):1542-6. PubMed ID: 18294304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
    Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
    Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Fisfis J; Perimenis P; Barbalias G
    J Urol; 2003 Jun; 169(6):2253-6. PubMed ID: 12771763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates.
    Lepor H; Nieder A; Feser J; O'Connell C; Dixon C
    Urology; 1997 Mar; 49(3):476-80. PubMed ID: 9123722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    Witjes WP; Rosier FW; de Wildt MJ; van Iersel MP; Debruyne FM; de La Rosette JJ
    J Urol; 1996 Apr; 155(4):1317-23. PubMed ID: 8632523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement.
    Witjes WP; de Wildt MJ; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
    J Urol; 1996 Sep; 156(3):1026-34. PubMed ID: 8709301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up?
    Rigatti L; Naspro R; Salonia A; Centemero A; Ghezzi M; Guazzoni G; Briganti A; Rigatti P; Montorsi F
    Urology; 2006 Jun; 67(6):1193-8. PubMed ID: 16750253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
    Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate.
    Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S
    Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transurethral microwave therapy in 200 patients with a minimum followup of 2 years: urodynamic and clinical results.
    Thalmann GN; Mattei A; Treuthardt C; Burkhard FC; Studer UE
    J Urol; 2002 Jun; 167(6):2496-501. PubMed ID: 11992066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.